Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.62 |
| ▸ | DDB1 | Q16531 | 17/20 | 0.62 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
| ▸ | IL1B | P01584 | 1/20 | 0.50 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31443763 | 0.93 | CRBN (0.71) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL3650600 | 0.93 | CRBN (0.71) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL23979366 | 0.91 | DDB1 (0.62) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL23979411 | 0.89 | CRBN (0.65) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL23979390 | 0.87 | CRBN (0.62) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL23979591 | 0.87 | CRBN (0.62) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL23979449 | 0.87 | CRBN (0.62) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL4098125 | 0.84 | DDB1 (0.71) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL23979400 | 0.84 | CRBN (0.59) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL23979394 | 0.84 | DDB1 (0.59) | CRBNDDB1TNFIL1BIKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773080-B2 | Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same | SALARIUS PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210340125-A1 | DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | SALARIUS PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773080-B2 | Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same | HPGDS, HPGD, AQP3 | CRBN 1079/4885DDB1 690/4885TNF 2820/4885 |
| US-20210340125-A1 | DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | HPGDS, HPGD, AQP3 | CRBN 1079/4885DDB1 690/4885TNF 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.